ArticleNeurology and therapy2022

Real-World Assessment of Quality of Life in Patients with Relapsing Remitting Multiple Sclerosis Treated with Teriflunomide for Two Years: Patient-Reported Outcomes from the AURELIO Study in Greece.

Efthymios Dardiotis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.